Anavex Life Sciences (AVXL) to Release Earnings on Tuesday

Key Points

• Anavex Life Sciences will report Q2 2026 results before the market opens on Tuesday, May 12, 2026, with analysts expecting ($0.07) EPS and the earnings call scheduled for 8:30 AM ET.
• In its last report the company posted ($0.06) EPS, beating estimates of ($0.10); analysts now expect $0 EPS for the current fiscal year and -$1 for the next fiscal year.
• Shares trade near $3.34 (market cap ~$309M) while the consensus analyst target is $21.33 amid mixed ratings (three Buys, one Hold, one Sell), signaling large implied upside but considerable uncertainty.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) will likely be posting its Q2 2026 results before the market opens on Tuesday, May 12th. Analysts expect Anavex Life Sciences to post earnings of ($0.07) per share for the quarter. Interested persons are encouraged to explore the company's upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04. On average, analysts expect Anavex Life Sciences to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Stock Performance

NASDAQ AVXL traded down $0.07 during mid-day trading on Tuesday, reaching $3.34. 231,942 shares of the stock were exchanged, compared to its average volume of 1,406,132. The company has a market capitalization of $309.52 million, a P/E ratio of -7.26 and a beta of 1.24. Anavex Life Sciences has a 1 year low of $2.61 and a 1 year high of $13.99. The business's 50 day moving average is $3.78 and its 200-day moving average is $4.61.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wyoming purchased a new position in shares of Anavex Life Sciences in the second quarter valued at approximately $26,000. Quarry LP purchased a new position in shares of Anavex Life Sciences in the third quarter valued at approximately $36,000. Russell Investments Group Ltd. boosted its stake in shares of Anavex Life Sciences by 11,540.0% in the third quarter. Russell Investments Group Ltd. now owns 6,984 shares of the biotechnology company's stock valued at $62,000 after purchasing an additional 6,924 shares during the period. Prudential Financial Inc. purchased a new position in shares of Anavex Life Sciences in the second quarter valued at approximately $95,000. Finally, Sei Investments Co. purchased a new position in shares of Anavex Life Sciences in the second quarter valued at approximately $107,000. Hedge funds and other institutional investors own 31.55% of the company's stock.

Analyst Ratings Changes

AVXL has been the subject of a number of recent research reports. D. Boral Capital reiterated a "buy" rating and issued a $24.00 target price on shares of Anavex Life Sciences in a research report on Tuesday, March 31st. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Anavex Life Sciences in a research report on Tuesday, February 10th. Rodman & Renshaw initiated coverage on shares of Anavex Life Sciences in a research report on Monday. They issued a "buy" rating and a $20.00 target price for the company. Wall Street Zen upgraded shares of Anavex Life Sciences from a "sell" rating to a "hold" rating in a research report on Saturday, February 14th. Finally, Weiss Ratings upgraded shares of Anavex Life Sciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, April 22nd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $21.33.

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company's lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer's disease and Parkinson's disease dementia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.